4//SEC Filing
ENRIGHT PATRICK G 4
Accession 0001104659-24-100333
CIK 0001953926other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 8:57 PM ET
Size
21.3 KB
Accession
0001104659-24-100333
Insider Transaction Report
Form 4
ENRIGHT PATRICK G
Director
Transactions
- Conversion
Common Stock
2024-09-16+334,530→ 334,530 total(indirect: See Footnote) - Conversion
Series C Convertible Preferred Stock
2024-09-16−2,904,764→ 0 total(indirect: See Footnote)→ Common Stock (334,530 underlying) - Conversion
Common Stock
2024-09-16+1,003,592→ 1,727,404 total(indirect: See Footnote) - Purchase
Common Stock
2024-09-16$17.00/sh+440,000$7,480,000→ 774,530 total(indirect: See Footnote) - Conversion
Common Stock
2024-09-16+723,812→ 723,812 total(indirect: See Footnote) - Award
Stock Option (Right to Buy)
2024-09-12+37,000→ 37,000 totalExercise: $17.00Exp: 2034-09-11→ Common Stock (37,000 underlying) - Conversion
Series B Convertible Preferred Stock
2024-09-16−6,284,933→ 0 total(indirect: See Footnote)→ Common Stock (723,812 underlying) - Conversion
Series C Convertible Preferred Stock
2024-09-16−8,714,293→ 0 total(indirect: See Footnote)→ Common Stock (1,003,592 underlying)
Footnotes (6)
- [F1]On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F2]Shares held by Longitude Venture Partners IV, L.P. ("LVPIV").
- [F3]Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Longitude Prime Partners, LLC ("LPP") is the general partner of Longitude Prime Fund, L.P. ("LPF") and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the board of directors of the Issuer, are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LCPIV, LPP, Ms. Bakker and Mr. Enright disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
- [F4]On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F5]Shares held by LPF.
- [F6]The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service.
Documents
Issuer
Zenas BioPharma, Inc.
CIK 0001953926
Entity typeother
Related Parties
1- filerCIK 0001253886
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 8:57 PM ET
- Size
- 21.3 KB